Is Compounded Semaglutide Safe? What FDA Oversight Means

You have seen headlines about FDA warnings on compounded GLP-1 medications. You have read stories about people having bad experiences. And now you are wondering: is compounded semaglutide actually safe? Should I use it?

The honest answer is more specific than a simple yes or no. Compounded semaglutide from a legitimate, state-licensed US 503A/503B compounding pharmacy has a fundamentally different safety profile than something you might buy from an unregulated online source or from a compounding operation flagged by the FDA for misconduct. This page explains what the regulatory landscape actually tells us, what the recent FDA concerns were really about, and how to think clearly about risk.

The short answer

Compounded semaglutide from a legitimate US-based, state-licensed compounding pharmacy is not the same as unregulated products purchased online from unknown sources.

It is also not FDA-approved. That distinction matters and should factor into your decision.

Here is what that means in practice:

Compounded semaglutide is legal under federal pharmacy compounding law^[1]. Semaglutide is on the FDA drug shortage list, which permits licensed compounding pharmacies to prepare it^[2]. The legal framework exists.

Compounded semaglutide is not FDA-approved for safety, efficacy, or quality. The FDA has not reviewed the specific compounded product you receive the way it reviewed brand-name semaglutide. This is a structural fact, not a criticism. It is something to understand before choosing compounded over branded.

Quality depends on the pharmacy that prepares your medication. A pharmacy that batch tests each preparation for potency and purity, sources APIs from FDA-registered suppliers, and operates under state pharmacy board oversight has a fundamentally different risk profile than a pharmacy that does not. The difference matters.

The FDA has taken enforcement action against specific compounders and telehealth companies for misconduct, including sourcing concerns, incorrect salt forms, and misleading marketing. These warnings targeted specific operations, not all compounded semaglutide.

What “safe” means (and doesn’t mean) for compounded medications

When people ask whether a compounded medication is safe, they are often asking whether it has been evaluated for quality and whether it is free of contamination or dosing errors. Safety for compounded medications is a different framework than the FDA approval process that applies to brand-name products.

FDA approval means a drug has undergone clinical trials in specific populations, at specific doses, for specific indications. The FDA reviewed the data and determined the drug’s benefits outweigh its risks for that approved use. Compounded medications skip that process entirely.

What exists for compounded medications instead:

State pharmacy licensing. The pharmacy holds an active license from the state pharmacy board where it operates. You can verify this on your state’s pharmacy board website.

PCAB accreditation (voluntary). The Pharmacy Compounding Accreditation Board (PCAB) certifies pharmacies that meet quality standards beyond the regulatory minimum. This is not required, but it is a meaningful quality signal.

Batch testing and certificate of analysis (COA). A responsible compounding pharmacy provides a COA for each batch, showing independent lab testing for potency and purity. Not all compounders do this, but those that do are operating at a higher standard.

Provider oversight. Your prescription comes from a licensed provider who has reviewed your health history and determined whether semaglutide is appropriate for you.

API sourcing from FDA-registered suppliers. Active pharmaceutical ingredients prepared by a licensed 503A/503B compounding pharmacy should come from FDA-registered suppliers. Some compounders have sourced from overseas or unverified suppliers, which is a red flag the FDA has flagged.

None of this means the medication is FDA-approved. It means there are meaningful guardrails in place.

Why the safety conversation became urgent: FDA enforcement in 2024-2025

In September 2025, the FDA announced a broad enforcement action against misleading GLP-1 telehealth marketing^[3]. Since then, the FDA has issued multiple warning letters to compounding pharmacies and telehealth companies^[4]. Here is what was actually flagged:

Incorrect semaglutide salt forms. Some compounders used semaglutide sodium or semaglutide acetate when only the base form of semaglutide may be used per PCCA^[5]. The salt forms are different molecular entities from the base form studied in the clinical trials that supported brand-name product approvals. Using the wrong form is a compounding error with potential clinical consequences.

Overseas-sourced APIs. Some pharmacies sourced active pharmaceutical ingredients from outside the United States or from unverified suppliers, rather than from FDA-registered pharmaceutical suppliers. This creates quality and consistency risks.

Unusual concentrations and dosing errors. Some products were compounded at non-standard concentrations, leading to confusion about dosing and potential for errors. One person reported receiving a vial that was supposed to contain multiple weeks’ worth of medication in a single vial (an unsafe concentration).

Misleading marketing claims. Some telehealth companies marketed compounded semaglutide using prohibited sameness language, terms that falsely imply a “generic” relationship to branded products, or unsubstantiated weight loss claims. These claims are false and violate FTC and FDA rules.

No prescription requirement. Some online sources offered semaglutide without requiring a valid prescription from a treating provider, which is illegal and indicates an unscrupulous operation.

These are real concerns. They represent actual problems that happened at specific pharmacies and telehealth operations. They are not a blanket indictment of all compounded semaglutide.

What distinguishes legitimate from illegitimate

A state-licensed compounding pharmacy sourcing legitimate compounded semaglutide operates differently from the problematic operations the FDA targeted.

Green flags (a legitimate compounding pharmacy):

State pharmacy board license. The pharmacy holds an active, verifiable state pharmacy license. You should be able to check this on your state’s pharmacy board website.

Semaglutide base. The pharmacy uses semaglutide base (the form used in FDA-approved brand-name GLP-1 medications), not semaglutide sodium or acetate salt forms.

FDA-registered API suppliers. Active pharmaceutical ingredients are sourced from FDA-registered, US-based pharmaceutical suppliers. The pharmacy can document this.

Certificate of analysis. Each batch has been tested for purity, potency, and sterility by an independent laboratory. The pharmacy provides a COA to patients upon request.

PCAB accreditation. The pharmacy holds voluntary accreditation from the Pharmacy Compounding Accreditation Board^[6], indicating commitment to quality standards.

Prescription required. You cannot obtain medication without a valid prescription from a licensed provider who has evaluated your health history.

Provider vetting. The telehealth or medical company you work with has vetted the pharmacy partner and maintains oversight of quality and compliance.

Red flags (likely illegitimate or lower-quality):

No prescription requirement. Sells without requiring a prescription from a treating provider.

Will not provide COA. Cannot or will not provide a certificate of analysis for batch testing.

Overseas-sourced APIs. Sources ingredients from outside the United States or cannot document US sourcing.

Extremely low prices. Pricing so low it does not support pharmacy-grade quality and testing practices.

No verifiable state license. No active state pharmacy license or the license cannot be verified.

Misleading marketing. Uses prohibited sameness language comparing compounded products to brand-name GLP-1 medications, falsely labels the compounded product with “generic” terminology, or makes unsubstantiated weight loss promises.

Vague about sourcing. Cannot clearly explain where the medication comes from, who compounded it, or what quality assurances are in place.

What Transformation Health does

When you work with Transformation Health, here is what happens:

You work with an independent, licensed provider. An independent healthcare provider reviews your health history, current medications, and medical conditions. They determine whether semaglutide is clinically appropriate for you. Not all patients qualify.

Your prescription goes to a vetted pharmacy partner. Transformation Health works exclusively with US-based, state-licensed compounding pharmacies that meet rigorous quality standards. Our pharmacy partners:

• Hold active state pharmacy licenses
• Source APIs exclusively from FDA-registered suppliers
• Provide certificate of analysis for each batch
• Are subject to ongoing quality monitoring and compliance oversight

You receive your medication with documentation. Your compounded semaglutide is shipped to your door with a COA from the pharmacy. You should review this documentation and ask questions if anything is unclear.

You are monitored by your provider. Your provider tracks your response to the medication, orders any necessary lab work, and adjusts your plan based on your results and side effects.

The regulatory status: Why compounded semaglutide is legal (for now)

Compounded semaglutide exists because semaglutide is on the FDA’s official drug shortage list^[7]. Federal law permits licensed compounding pharmacies to prepare copies of drugs on the shortage list to ensure patients can continue accessing necessary medications.

This is an important point: the legal basis for compounding is tied to the shortage designation. If and when semaglutide is removed from the FDA drug shortage list entirely (as branded versions become more widely available), the legal foundation for continued compounding may shift.

Transformation Health monitors the regulatory landscape. As the situation evolves and shortage designations change, availability of compounded semaglutide may change. We work with our pharmacy partners to ensure we always operate within the law.

The bottom line for your decision

If you have been reading scary headlines, here is what to understand:

Compounded semaglutide from a vetted, legitimate US pharmacy is not the same as unregulated products. The difference between a pharmacy that sources APIs from verified suppliers, tests each batch, and requires a valid prescription is substantial. Quality matters.

It is still not FDA-approved. This distinction is important. Brand-name semaglutide went through FDA clinical review. Compounded semaglutide did not. Whether that trade-off is acceptable is a decision you and your provider make together.

The right approach is informed decision-making. Ask where your medication comes from. Verify your pharmacy’s credentials. Request the certificate of analysis for your batch. Ask your provider about the pharmacy they are working with. A trustworthy provider and pharmacy will have clear answers.

Compounded semaglutide can be a legitimate option for appropriate patients. When sourced responsibly, prescribed by a provider who knows your health history, and compounded to proper standards, it offers an accessible pathway to medication that is not available through other means for many people.

Your decision should be based on your health situation, your provider’s recommendation, your comfort level with the regulatory trade-off between compounded and branded medications, and your access to insurance coverage.

What you should ask before starting

If you are considering compounded semaglutide through any provider or pharmacy, ask these questions directly:

1. Where is the compounding pharmacy located, and what is their state license number?
2. What is the source of the semaglutide API? (Should be: a US-based, FDA-registered pharmaceutical supplier.)
3. What form of semaglutide is used? (Should be: semaglutide base, not sodium or acetate.)
4. Can I have a certificate of analysis for my specific batch?
5. Is the pharmacy PCAB-accredited?
6. Has the pharmacy ever received an FDA warning letter or state board violation?
7. What is the standard concentration of your semaglutide vials?
8. What happens if I have side effects or dosing concerns?

A legitimate pharmacy and provider will answer these questions directly and transparently.

The role of provider oversight

One of the most important safety elements is provider oversight. At Transformation Health, this is non-negotiable.

Your provider is not just writing a prescription. Your provider is responsible for determining whether compounded semaglutide is appropriate for your specific health history. They are monitoring your response to the medication. They are ordering labs when needed. They are adjusting your plan based on your results.

A provider who knows your health history, understands the difference between compounded and branded semaglutide, and maintains oversight throughout your program is a safety feature in itself.

Telehealth makes it possible to connect with licensed providers without visiting an office. What it does not do, and must not do, is replace medical judgment. If you are working with a telehealth provider who does not ask about your health history or who seems to be rushing through prescription decisions, that is a red flag.

The bigger picture: balancing access and regulation

Here is the reality: for many people, brand-name GLP-1 medications are not accessible. They are costly, insurance often does not cover them for weight management, and wait times can be long. Compounded semaglutide exists partly because brand-name GLP-1 medications are not universally accessible.

This does not mean compounded is as safe or as thoroughly tested as branded. It means compounded is a real option when branded is not available or affordable. The safety analysis should be: compared to what? Compared to unregulated online sources, compounded from a legitimate pharmacy is significantly safer. Compared to FDA-approved branded medications, compounded carries more uncertainty.

Your decision is about which trade-off makes sense for your situation.

Residents of AR, DC, DE, MS, NM, RI, and WV are required by state law to complete a live video consultation with a provider before a prescription can be written.

What FDA Adverse Event Reports Show

Since July 2024, the FDA has documented significant safety issues tied to compounded semaglutide. As of April 2025, the agency had received over 520 adverse event reports related to compounded semaglutide^[8]. These were not theoretical concerns, but actual patient incidents.

The documented adverse events included hospitalization for nausea, vomiting, abdominal pain, fainting, headache, migraine, dehydration, acute pancreatitis, and gallstones^[9]. Some of these cases involved doses that were 5 to 20 times the intended amount, raising the most critical question: why did this happen?

The root causes fell into a few clear categories:

Unit confusion. The most common error involved mixing up milligrams and units. Semaglutide is dosed in units (0.6 mg, 1.2 mg, 1.8 mg per injection), but some patients and providers calculated doses thinking they were measuring in different units. This led to dramatically over-dosing. For example, someone who was supposed to take a 0.6 mg dose might instead receive 6 mg or more due to misunderstanding how their vial was labeled or measured.

Non-standardized vial concentrations. Different compounding pharmacies prepared semaglutide at different concentrations, with no industry standard. One pharmacy might prepare 1 mg/mL while another prepared 2 mg/mL. Without clear communication or standardized labeling, patients and providers could be confused about how much medication was actually in each vial or syringe.

Patient self-adjustment. Some patients, not seeing rapid results at prescribed doses, increased their own doses without consulting their provider, leading to overdoses.

Critically: These adverse events occurred overwhelmingly with online sellers, non-accredited compounders, and sources outside the regulated pharmacy network, not with PCAB-accredited 503A pharmacies subject to state pharmacy board oversight^[10].

What to do if you think you have taken too much

If you believe you have taken a higher dose than intended, contact your prescribing provider immediately. If you are experiencing severe symptoms, seek emergency care. Symptoms of overdose include severe nausea and vomiting, severe dehydration, fainting, chest pain, or difficulty breathing. Do not wait to see if symptoms resolve on their own.

Counterfeit and Illegitimate Products

The FDA has issued explicit warnings about counterfeit semaglutide products sold online. These are not just mislabeled compounded products, but fraudulent items with fake manufacturer labels designed to deceive consumers^[11].

What the FDA has found:

Products with false pharmacy labels. Some fraudulent compounded products have labels bearing the names of compounding pharmacies that do not exist, or they falsely claim to have been compounded by licensed pharmacies that actually did not compound them^[12].

Counterfeit semaglutide products with wrong or missing active ingredients. The FDA has seized counterfeit semaglutide products that contained the wrong active ingredient entirely, too little or too much active ingredient, or no active ingredient at all^[13]. Some counterfeit samples have included counterfeit needles whose sterility cannot be confirmed, increasing infection risk.

Products marketed as “research only” or “not for human consumption” but sold with dosing instructions for human use, designed to evade regulatory oversight^[14].

How to verify legitimacy

A legitimate semaglutide source meets all of these criteria:

The source is a state-licensed 503A or 503B pharmacy. You should be able to verify the pharmacy’s license on your state pharmacy board website.

A valid prescription from a licensed US provider is required before you can obtain the medication. If no prescription is required, it is not legitimate.

The medication comes with a lot number, expiration date, and pharmacy contact information on the label.

For compounded products, a certificate of analysis from independent batch testing is available upon request.

Red flags for counterfeit or illegitimate products

Sold without requiring a valid prescription from a licensed provider. This violates federal law.

Shipped from outside the United States, or the seller is evasive about where it ships from.

Sold via social media, messaging apps, unverified online pharmacies, or non-pharmacy websites.

Pricing dramatically lower than legitimate sources (typically $150–300/month for compounded semaglutide). If it seems too cheap to be real, it is.

No way to verify the pharmacy or pharmacy license. The seller cannot provide a pharmacy name and state license number, or the number does not check out.

Labels that look unprofessional, have misspellings, or bear the names of major brand-name manufacturers when the product is claimed to be “compounded.”

Salt Form Accuracy: Semaglutide Base vs. Semaglutide Sodium

This is a technical point that matters for your safety. Semaglutide can exist in two forms: semaglutide base or semaglutide sodium salt. These are not interchangeable, and using the wrong salt form without accounting for the dosing difference can result in under- or over-dosing.

The difference:

Semaglutide base is the active ingredient used in FDA-approved brand-name semaglutide. It is the only form that has been studied in clinical trials for humans^[15].

Semaglutide sodium and semaglutide acetate are salt forms. These have different molecular weights and different bioavailability (how much the body absorbs) compared to the base form. The FDA has stated it does not have information on whether these salts behave the same way in the human body as the base form^[16].

Why this matters for compounding:

Some compounding pharmacies have used semaglutide sodium or acetate instead of semaglutide base, often unknowingly or without properly adjusting the dose calculations^[17]. The FDA has explicitly warned that salt forms of semaglutide should not be used in compounded products.

If a compounder uses semaglutide sodium without accounting for the different molecular weight, the final concentration might be significantly higher or lower than labeled, creating a dosing error even if both the compounder and the patient follow the instructions correctly.

Questions to ask your pharmacy

Before you receive your first dose, ask your compounding pharmacy directly:

1. What form of semaglutide API do you use: base or salt form?
2. If you use semaglutide base, where is it sourced from? (Should be an FDA-registered US pharmaceutical supplier.)
3. Can you provide documentation showing the molecular form and potency of your API?
4. Is your concentration calculation based on semaglutide base or another form?

A legitimate compounding pharmacy will provide clear, specific answers. They use semaglutide base sourced from verified suppliers, and they account for this in their concentration calculations. They can document this.

At Transformation Health, our pharmacy partners use USP-grade semaglutide base with standardized concentrations and complete batch testing documentation. We verify API sourcing and form as part of our vetting process for any pharmacy partner.

Citations

[1] FDA. “Compounding and the FDA: Questions and Answers.” https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

[2] FDA. “Drug Shortages Database.” https://www.accessdata.fda.gov/scripts/drugshortages/

[3] FDA. “Drug Alerts and Statements.” U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-safety-and-availability/drug-alerts-and-statements

[4] FDA. “Warning Letters on GLP-1 Marketing.” https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws

[5] FDA. “Guidance: Semaglutide Salt Forms in Compounded Products.” https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws

[6] Pharmacy Compounding Accreditation Board. “PCAB Accreditation Standards.” https://www.pcab.org/

[7] FDA. “Drug Shortages List.” https://www.accessdata.fda.gov/scripts/drugshortages/

[8] FDA. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

[9] FDA. “FDA Alerts Healthcare Providers and Compounders of Dosing Errors Associated with Compounded Semaglutide Products” (July 2024). Adverse event reports archived at FDA MedWatch.

[10] Renal and Urology News. “FDA: Dosing Errors, Adverse Events Reported With Compounded Semaglutide.” https://www.renalandurologynews.com/news/fda-dosing-errors-adverse-events-reported-with-compounded-semaglutide/

[11] FDA. “FDA Warns Consumers Not to Use Counterfeit Semaglutide Products Found in U.S. Drug Supply Chain.” https://www.fda.gov/drugs/drug-safety-and-availability/drug-alerts-and-statements

[12] Healio. “FDA Cautions Public, Providers to Avoid Use of Compounded Salt Forms of Semaglutide.” https://www.healio.com/news/endocrinology/20230531/fda-cautions-public-providers-to-avoid-use-of-compounded-salt-forms-of-semaglutide

[13] US Pharmacist. “FDA Warns About Counterfeit, Improperly Compounded Semaglutide Products.” https://www.uspharmacist.com/article/fda-warns-about-counterfeit-improperly-compounded-semaglutide-products

[14] Healio. “FDA Cautions Public, Providers to Avoid Use of Compounded Salt Forms of Semaglutide.” https://www.healio.com/news/endocrinology/20230531/fda-cautions-public-providers-to-avoid-use-of-compounded-salt-forms-of-semaglutide

[15] Mississippi Board of Pharmacy. “Semaglutide Compounding Guidance.” https://www.mbp.ms.gov/sites/default/files/inline-images/Semaglutide.compoundguidance%20(002).pdf

[16] FDA. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

[17] FDA. “Guidance: Semaglutide Salt Forms in Compounded Products.” Referenced in multiple state pharmacy board statements and FDA enforcement actions.